-
公开(公告)号：US08871913B2
公开(公告)日：2014-10-28
申请号：US14260975
申请日：2014-04-24
Applicant: Amgen, Inc.
Inventor： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Wenyan Shen , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo
CPC classification number: C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C12N15/1137 , A61K2300/00
Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
公开(公告)号：US20140235831A1
公开(公告)日：2014-08-21
申请号：US14260985
申请日：2014-04-24
Applicant: Amgen, Inc.
Inventor： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Wenyan Shen , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C12N15/1137 , A61K2300/00
Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
33.发明申请ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) 有权抗原蛋白质结合蛋白转移酶突变体KEXIN 9型（PCSK9）公开(公告)号：US20140228545A1
公开(公告)日：2014-08-14
申请号：US14261087
申请日：2014-04-24
Applicant: Amgen, Inc.
Inventor： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo , Qiong Cao
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C12N15/1137 , A61K2300/00
Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Abstract translation: 描述了与Proprotein转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）相互作用的抗原结合蛋白。 描述了通过向PCSK9施用药学有效量的抗原结合蛋白来治疗高胆固醇血症和其它病症的方法。 描述了使用抗原结合蛋白质向PCSK9检测样品中PCSK9的量的方法。
-
公开(公告)号：US20240010724A1
公开(公告)日：2024-01-11
申请号：US17933277
申请日：2022-09-19
Applicant: AMGEN INC. , AMGEN RESEARCH (MUNICH) GMBH
Inventor： Shouhua Xiao , Zheng Pan , Dineli Wickramasinghe , M. Shawn Jeffries , Chadwick Terence King , Brian Mingtung Chan , Peter Kufer , Ralf Lutterbüse , Tobias Raum , Patrick Hoffmann , Doris Rau , Roman Kischel , Bryan Lemon , Holger Wesche
CPC classification number: C07K16/2809 , C07K16/28 , C07K16/3053 , A61K2039/505 , C07K16/2896 , C07K16/468 , A61K47/60
Abstract: The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
-
公开(公告)号：US11498964B2
公开(公告)日：2022-11-15
申请号：US16040927
申请日：2018-07-20
Applicant: AMGEN RESEARCH (MUNICH) GMBH , AMGEN INC.
Inventor： Shouhua Xiao , Zheng Pan , Dineli Wickramasinghe , M. Shawn Jeffries , Chadwick Terence King , Brian Mingtung Chan , Peter Kufer , Ralf Lutterbüse , Tobias Raum , Patrick Hoffmann , Doris Rau , Roman Kischel , Bryan Lemon , Holger Wesche
Abstract: The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.
-
Patent Agency Ranking
公开(公告)号：US10526411B2
公开(公告)日：2020-01-07
申请号：US15665139
申请日：2017-07-31
Applicant: AMGEN INC.
Inventor： Chadwick Terence King , Gordon Ng , Shaw-Fen Sylvia Hu , Hung Nguyen , Jeannie Jung
Abstract: The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.
-
公开(公告)号：US10227406B2
公开(公告)日：2019-03-12
申请号：US14899551
申请日：2014-06-25
Applicant: AMGEN INC.
Inventor： Peter Coward , Steven A. Moore, Jr. , Shi-Yuan Meng , Mei-Mei Tsai , Chadwick Terence King , Aaron Avraham Nazarian
IPC: C07K16/28
Abstract: This disclosure relates to CB1 receptor antigen-binding proteins, e.g. antibodies and methods of using the CB1 receptor antibodies. The CB1 receptor antibodies may comprise an antagonistic antibody to CB1 receptors and may be used to treat various health conditions. The health conditions can comprise obesity or diabetes or any disease that benefits from antagonism of the CB1 receptor.
-
公开(公告)号：US20170267775A1
公开(公告)日：2017-09-21
申请号：US15402478
申请日：2017-01-10
Applicant: AMGEN INC.
IPC: C07K16/30 , A61K39/395 , A61K31/5365 , C07K16/28
CPC classification number: C07K16/30 , A61K31/5365 , A61K39/39558 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K16/2875 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.
-
39.发明申请NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) 审中-公开核酸抗体结合蛋白编码转化子分泌素KEXIN 9型（PCSK9）公开(公告)号：US20140357854A1
公开(公告)日：2014-12-04
申请号：US14459844
申请日：2014-08-14
Applicant: Amgen Inc.
Inventor： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo , Qiong Cao
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C12N15/1137 , A61K2300/00
Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Abstract translation: 描述了与Proprotein转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）相互作用的抗原结合蛋白。 描述了通过向PCSK9施用药学有效量的抗原结合蛋白来治疗高胆固醇血症和其它病症的方法。 描述了使用抗原结合蛋白质向PCSK9检测样品中PCSK9的量的方法。
-
40.发明申请公开(公告)号：US20140357853A1
公开(公告)日：2014-12-04
申请号：US14459768
申请日：2014-08-14
Applicant: Amgen Inc.
Inventor： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo , Qiong Cao
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C12N15/1137 , A61K2300/00
Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
-
-
-
-
-
-
-
-
Search Results
45
records
(took 0.037 seconds)
